HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
暂无分享,去创建一个
Y Sakai | S. Nishikawa | K. Alitalo | Y. Yamaoka | M. Ogawa | T. Fujiwara | Y. Sakai | Y Yamaoka | K Alitalo | H. Kubo | Y. Sakai | K. Shimizu | A Takabayashi | L Jussila | S I Nishikawa | A. Takabayashi | H Kubo | T Fujiwara | H Hashi | M Ogawa | K Shimizu | M Awane | H. Hashi | M. Awane | L. Jussila | Takashi Fujiwara | Kenji Shimizu | Yoshio Yamaoka
[1] K. Alitalo,et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. , 1997, Developmental biology.
[2] K. Alitalo,et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[4] S. Nishikawa,et al. Expressions of PDGF receptor alpha, c‐Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells , 1997, Development, growth & differentiation.
[5] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[6] K. Alitalo,et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] K. Alitalo,et al. Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] M Aguet,et al. VEGF is required for growth and survival in neonatal mice. , 1999, Development.
[9] D. Connolly. Vascular permeability factor: A unique regulator of blood vessel function , 1991, Journal of cellular biochemistry.
[10] K. Alitalo,et al. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. , 1994, Oncogene.
[11] D. Merberg,et al. Molecular cloning of murine FLT and FLT4. , 1993, Oncogene.
[12] R. Jain,et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.
[13] K. Alitalo,et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia , 1997, Oncogene.
[14] 平島 正則. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis , 1999 .
[15] K. Alitalo,et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.
[16] A. Ullrich,et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.
[17] K. Toda,et al. Establishment and characterization of a tumorigenic murine vascular endothelial cell line (F-2). , 1990, Cancer research.
[18] Douglas Hanahan,et al. Signaling Vascular Morphogenesis and Maintenance , 1997, Science.
[19] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.
[20] Per BorgstrÃ. Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-Vascular Endothelial Growth Factor Neutralizing Antibody : Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy , 2022 .
[21] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[22] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[23] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[24] A. Ullrich,et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.
[25] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[26] K. Alitalo,et al. Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.
[27] A. Eichmann,et al. Expression of the avian VEGF receptor homologues Quek1 and Quek2 in blood-vascular and lymphatic endothelial and non-endothelial cells during quail embryonic development , 1997, Cell and Tissue Research.
[28] A. Harris,et al. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] K. Hori,et al. In vivo Analysis of Tumor Vascularization in the Rat , 1990, Japanese journal of cancer research : Gann.
[30] Janet Rossant,et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.
[31] Yihai Cao,et al. Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.
[32] M. Dewhirst,et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.
[33] Pamela F. Jones,et al. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.
[34] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[35] S. Nishikawa,et al. Distinct stages of melanocyte differentiation revealed by anlaysis of nonuniform pigmentation patterns. , 1996, Development.
[36] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.